Comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine): Unveiling the strategy for lactation inhibition - A systematic review of clinical trials.
Level 1 - systematic review of randomized trials
Systematic review of clinical trials
PubMed 38554942 · doi:10.1016/j.jogoh.2024.102783
What was done
A systematic review conducted according to Cochrane Handbook guidelines searched databases including Cochrane Central, PubMed/MEDLINE, ScienceDirect, ClinicalTrials.gov, Web of Science, CINAHL, and Google Scholar through November 2023. The review evaluated clinical trials comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine) for postpartum lactation inhibition. Outcomes of interest included lactation inhibition, breast pain/tenderness, breast engorgement, milk secretion, fever, mastitis, prolactin levels, and adverse events. Risk of bias was evaluated using the Cochrane risk of bias tool.
What was found
Three clinical trials met inclusion criteria. On global assessment of therapeutic efficacy, dopaminergic agents achieved statistically significant lactation inhibition compared to pyridoxine (p < 0.001). The abstract provided no effect sizes, confidence intervals, total participant counts, or numerical data for adverse events or specific breast symptoms.
Why it matters
This review directly compares pyridoxine to dopamine agonists for postpartum lactation suppression, finding superior efficacy with cabergoline and bromocriptine.
Limits
The evidence base is limited to only three clinical trials. Total participant sample size is not reported in the abstract, and numerical outcome data, safety event rates, and risk-of-bias results are omitted.
Cited by
- supports Prescription drugs such as cabergoline inhibit prolactin secretion.